MX2017005497A - Uso de l. reuteri para la recuperacion de la disbiosis de microbiota en los primeros años de vida. - Google Patents

Uso de l. reuteri para la recuperacion de la disbiosis de microbiota en los primeros años de vida.

Info

Publication number
MX2017005497A
MX2017005497A MX2017005497A MX2017005497A MX2017005497A MX 2017005497 A MX2017005497 A MX 2017005497A MX 2017005497 A MX2017005497 A MX 2017005497A MX 2017005497 A MX2017005497 A MX 2017005497A MX 2017005497 A MX2017005497 A MX 2017005497A
Authority
MX
Mexico
Prior art keywords
microbiota dysbiosis
functional
disorders
disease
prevention
Prior art date
Application number
MX2017005497A
Other languages
English (en)
Inventor
Lucia Garcia-Rodenas Clara
Berger Bernard
NGOM-BRU Catherine
Lepage Melissa
NEVILLE Tara
Original Assignee
Biogaia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51897072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017005497(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogaia Ab filed Critical Biogaia Ab
Publication of MX2017005497A publication Critical patent/MX2017005497A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pediatric Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La invención se refiere a Lactobacillus reuteri para usar en la prevención o el tratamiento de la disbiosis de microbiota, particularmente, menores niveles de Actinobacteria y mayores niveles de Proteobacteria, en mamíferos jóvenes y en la prevención o el tratamiento de trastornos asociados con esta. La disbiosis de microbiota puede haberse provocado por numerosos factores, que incluyen el nacimiento por sección cesárea, exposición a antibióticos in utero o después del nacimiento, o alimentación parenteral, hospitalización, estrés psicológico o por disfunciones gastrointestinales. Los trastornos que pueden tratarse o prevenirse mediante la prevención o el tratamiento de la disbiosis de microbiota incluyen propensión a la infección, alergia, diabetes mellitus tipo I, resistencia a la insulina, diabetes tipo 2, enfermedad celíaca, adiposidad periférica y central, obesidad, enterocolitis necrotizante, enfermedad inflamatoria del intestino, tal como la enfermedad de Crohn y colitis ulcerosa, y trastornos gastrointestinales funcionales, tales como lBS, diarrea funcional, estreñimiento funcional, dolor abdominal recurrente y dispepsia.
MX2017005497A 2014-10-29 2015-10-29 Uso de l. reuteri para la recuperacion de la disbiosis de microbiota en los primeros años de vida. MX2017005497A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14190941 2014-10-29
PCT/EP2015/075164 WO2016066763A1 (en) 2014-10-29 2015-10-29 Use of l. reuteri for recovery of microbiota dysbiosis in early life

Publications (1)

Publication Number Publication Date
MX2017005497A true MX2017005497A (es) 2017-09-15

Family

ID=51897072

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005497A MX2017005497A (es) 2014-10-29 2015-10-29 Uso de l. reuteri para la recuperacion de la disbiosis de microbiota en los primeros años de vida.

Country Status (17)

Country Link
US (2) US11369646B2 (es)
EP (1) EP3212208B1 (es)
KR (2) KR20170072879A (es)
CN (2) CN116650541A (es)
AU (1) AU2015340605B2 (es)
BR (1) BR112017005612A2 (es)
CA (1) CA2960337C (es)
CL (1) CL2017000850A1 (es)
DK (1) DK3212208T3 (es)
ES (1) ES2870425T3 (es)
MX (1) MX2017005497A (es)
MY (1) MY186733A (es)
PH (1) PH12017500334B1 (es)
PL (1) PL3212208T3 (es)
RU (1) RU2723687C2 (es)
WO (1) WO2016066763A1 (es)
ZA (1) ZA201703635B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US12005085B2 (en) * 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
JP6754694B2 (ja) 2014-03-06 2020-09-16 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル プロバイオティクス製剤および使用のための方法
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
WO2016201519A1 (en) * 2015-06-16 2016-12-22 Murdoch Childrens Research Institute Method of treating crohn's disease
US20180207067A1 (en) 2015-07-14 2018-07-26 Research Institute at Nationwide Children's Hospit al Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
PL3445380T6 (pl) * 2016-04-19 2025-05-05 Genome Research Limited Bakterioterapia
EP4548925A3 (en) 2016-07-01 2025-07-09 Infinant Health, Inc Method for facilitating maturation of the mammalian immune system
US11179405B2 (en) 2016-09-07 2021-11-23 Societe Des Produits Nestle S.A. Nutritional compositions for infants and/or young children comprising oligosaccharides
EP3645023B1 (en) * 2017-06-30 2022-09-14 N.V. Nutricia Synbiotic composition for preventing hyperinsulinemia and insulin resistance
US11524019B2 (en) 2017-08-21 2022-12-13 Glycom A/S Synthetic composition for reducing allergy symptoms
EP3716984B1 (en) 2017-11-30 2024-03-20 Glycom A/S Mixture of hmos for treating wheat sensitivity
GB2573538B (en) * 2018-05-09 2023-01-04 Mjn Us Holdings Llc Pediatric nutritional compositions and methods for infants delivered by C-section
WO2020028871A1 (en) * 2018-08-03 2020-02-06 Research Institute At Nationwide Children's Hospital Prenatal probiotic formulations
US20220047653A1 (en) * 2018-08-10 2022-02-17 The Regents Of The University Of California Methods and compositions for treating and preventing inflammatory diseases
EP3870154A4 (en) * 2018-10-22 2022-07-27 Research Institute at Nationwide Children's Hospital COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ANTIBIOTIC-INDUCED PATHOLOGIES USING PROBIOTICS IN BIOFILM STATE
BR112021012118A2 (pt) * 2018-12-19 2021-09-08 Healthy Cow Corporation Composição probiótica em forma de gel, produto probiótico pronto para uso, kit, sistema, e, métodos para introduzir uma ou mais cepas de bactérias à vagina de um animal não humano, para tratar uma infecção uterina ou diminuir o risco de contrair uma infecção uterina em um animal não humano e para promover o estabelecimento ou manutenção de um microbioma vaginal saudável em um animal não humano
FR3093427B1 (fr) * 2019-03-05 2021-03-05 Mativa Tech Composition pour son utilisation dans la prévention et/ou le traitement de la dysbiose
EP3979830B1 (en) 2019-06-03 2025-11-26 Research Institute at Nationwide Children's Hospital Formulations for the treatment of neurodevelopmental deficiencies induced by necrotizing enterocolitis
KR102621775B1 (ko) * 2019-06-11 2024-01-08 씨제이바이오사이언스 주식회사 영유아의 장내 미생물 불균형도를 탐지하는 방법
CN110591945A (zh) * 2019-09-06 2019-12-20 吉林大学 一株用于预防溃疡性结肠炎的优良罗伊氏乳杆菌
KR102529206B1 (ko) * 2019-12-20 2023-05-08 충북대학교 산학협력단 신규한 락토바실러스 루테리 ｄｂ２ 균주 및 이의 용도
CN111254090B (zh) * 2019-12-30 2021-11-05 杭州娃哈哈科技有限公司 一株具有减肥功能的罗伊氏乳杆菌及其应用
CN111265553B (zh) * 2020-01-23 2021-06-22 湖南菲勒生物技术有限公司 一株母乳来源罗伊氏乳杆菌调节母婴免疫功能的应用
EP4056053A1 (en) * 2021-03-12 2022-09-14 Biogaia AB Pre-conditioning of l. reuteri
CN113180109B (zh) * 2021-04-16 2022-02-18 段云峰 罗伊氏乳杆菌在制备预防或治疗发育障碍类疾病产品中的应用
CN113073066B (zh) * 2021-04-16 2022-01-04 段云峰 罗伊氏乳杆菌及其应用、组合物、药物和食品
FR3126869A1 (fr) 2021-09-16 2023-03-17 Gozen K. K. Japan Composition pharmaceutique comprenant des métabolites issus de la bactérie Bacillus subtilis Gozen GZN-08 isolée de Camellia sinensis et modulant la réponse immunitaire.
CN114107088B (zh) * 2021-10-20 2023-07-21 山西大学 一种罗伊氏乳杆菌lrsy523及其应用
CN113943687B (zh) * 2021-12-21 2022-02-22 山东中科嘉亿生物工程有限公司 一种改善溃疡性结肠炎的罗伊氏乳杆菌jylb-291及其应用
CN114990004B (zh) * 2022-04-19 2023-09-15 尚品健康科技(青岛)有限公司 一种分泌型免疫球蛋白a包裹态罗伊氏乳杆菌及防治妊娠糖尿病的应用
EP4601663A1 (en) * 2022-10-13 2025-08-20 Baylor College of Medicine Secretin inducing bacteria
KR20240150943A (ko) 2023-04-10 2024-10-17 (주)인트젠 영유아용 유산균 프로바이오틱스 조성물
KR102752058B1 (ko) 2023-08-25 2025-01-13 전남대학교 산학협력단 락토바실러스 루터리 nchbl-005 균주, 사균체 또는 이의 혼합물을 유효 성분으로 포함하는 염증성 질환 예방, 치료 또는 개선용 조성물
WO2025206977A1 (ru) * 2024-03-29 2025-10-02 Александр Владимирович Синица Штамм бактерий lactobacillus reuteri, подавляющий активность helicobacter pylori
CN117982544B (zh) * 2024-04-03 2024-07-05 哈尔滨葵花药业有限公司 一株罗伊氏粘液乳杆菌Glory LR15在调节肥胖型哮喘产品中的应用
CN120192865A (zh) * 2024-11-07 2025-06-24 河北农业大学 一种罗伊氏粘液乳杆菌mry6及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374924B2 (en) * 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
EP1974743A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota
CN102065872A (zh) * 2008-05-27 2011-05-18 雀巢产品技术援助有限公司 改善肠微生物群的益生菌
EP2127661A1 (en) 2008-05-27 2009-12-02 Nestec S.A. Probiotics to improve gut microbiotica
EP2147678A1 (en) * 2008-07-21 2010-01-27 Nestec S.A. Probiotics to increase IgA secretion in infants born by caesarean section
EP2609813A1 (en) * 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system
CA2893217C (en) * 2012-12-18 2017-11-28 Abbott Laboratories Human milk oligosaccharides to ameliorate symptoms of stress
MX2016015153A (es) * 2014-05-20 2017-03-07 Biogaia Ab Complementacion de microbioma neonatal.

Also Published As

Publication number Publication date
US11701397B2 (en) 2023-07-18
RU2017118358A3 (es) 2019-03-05
US20220331380A1 (en) 2022-10-20
ZA201703635B (en) 2019-06-26
KR102606971B1 (ko) 2023-11-30
KR20220163503A (ko) 2022-12-09
PH12017500334B1 (en) 2023-07-05
WO2016066763A1 (en) 2016-05-06
AU2015340605A1 (en) 2017-03-16
AU2015340605B2 (en) 2021-06-24
US11369646B2 (en) 2022-06-28
RU2723687C2 (ru) 2020-06-17
PH12017500334A1 (en) 2017-07-17
CA2960337A1 (en) 2016-05-06
CN116650541A (zh) 2023-08-29
CL2017000850A1 (es) 2017-11-03
CN106794207A (zh) 2017-05-31
BR112017005612A2 (pt) 2017-12-12
PL3212208T3 (pl) 2021-09-06
EP3212208A1 (en) 2017-09-06
ES2870425T3 (es) 2021-10-27
RU2017118358A (ru) 2018-11-29
US20180280454A1 (en) 2018-10-04
KR20170072879A (ko) 2017-06-27
DK3212208T3 (da) 2021-05-17
EP3212208B1 (en) 2021-03-03
MY186733A (en) 2021-08-15
CA2960337C (en) 2022-04-05

Similar Documents

Publication Publication Date Title
PH12017500334A1 (en) Use of l. reuteri for recovery of microbiota dysbiosis in early life
MX2024001135A (es) Antagonistas de miostatina, activina o receptor de activina para el uso en el tratamiento de la obesidad y afecciones relacionadas.
MX2018010640A (es) Co-agonistas del glucagon y de glp-1 para el tratamiento de la obesidad.
MX2015015784A (es) Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
SMT201800072T1 (it) Ceppo innovativo di bifidobacterium animalis subsp. lactis cect 8145 e relativo uso per il trattamento e/o la prevenzione di peso in eccesso e obesita' e patologie correlate
TR201909078T4 (tr) Kimyasal bileşikler ve bunların kas kalitesinin iyileştirilmesine yönelik kullanımı.
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
IL282904A (en) Therapeutic microbiota for the treatment and/or prevention of dysbiosis
PH12019500496A1 (en) Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
ZA201900955B (en) Treatment of fecal matter by smoldering and catalysis
GB201205739D0 (en) Treatment of acute inflammation in the respiratory tract
GB2564514A (en) Health supplements
PH12019501439A1 (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
WO2015187727A3 (en) Molecular mammography
GB201617519D0 (en) A companion diagnostic method for use in the treatment of irritable bowel syndrome with dietary interventions or faecal microbiota transplant
PT3741218T (pt) Estirpe de lactobacillus salivarus e seu uso na prevenção e tratamento de diarreia pós-desmame em leitões
Triantafillidis et al. Treatment of inflammatory bowel disease patients with anti-TNF-α factors and immunosuppressives does not influence the prevalence of Helicobacter pylori infection
WO2017011559A8 (en) Compositions and methods for treating cancer
DK3366306T3 (en) Use of some peptides in diagnosis and treatment of diabetes, obesity and metabolic diseases associated thereto
Lytynska The role and place of probiotics in complex treatment of patients with psoriasis and eczema infectious associated with deterioration of intestinal microbiota
Yamamura Multiple Sclerosis and Commensal Gut Flora
Gao et al. Immunomodulation and signaling mechanism
邓莉 Evaluation of proximal gastric function in functional dyspepsia and its subtypes
郭振 Effects of exclusive enteral nutrition on the mucosal healing in adult patients with active Crohn's disease
肖琳 Randomized controlled trial of modified Banxia Houpo decoction in treating functional dyspepsia patients with psychological factors

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BIOGAIA AB